Compare CAR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAR | CRSP |
|---|---|---|
| Founded | 1946 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | 393 |
| Industry | Rental/Leasing Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 1998 | 2016 |
| Metric | CAR | CRSP |
|---|---|---|
| Price | $160.05 | $59.34 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $136.57 | $70.29 |
| AVG Volume (30 Days) | 710.6K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,652,000,000.00 | $289,590,000.00 |
| Revenue This Year | $2.10 | $807.72 |
| Revenue Next Year | $1.81 | $172.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $85.96 | $44.12 |
| 52 Week High | $847.70 | $78.48 |
| Indicator | CAR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 44.47 | 64.52 |
| Support Level | $155.00 | $58.40 |
| Resistance Level | $181.31 | $59.61 |
| Average True Range (ATR) | 9.24 | 2.85 |
| MACD | -2.45 | 0.52 |
| Stochastic Oscillator | 36.01 | 78.36 |
Avis Budget Group Inc is a provider of mobility solutions through its three brands Avis, Budget and Zipcar, as well as several other brands, well recognized in their respective markets. Its brands offer a range of options, from car and truck rental to car sharing. The company operates in two reportable business segments: Americas - (i) vehicle rental operations in North America, South America, Central America and the Caribbean, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly. International - consisting of (i) vehicle rental operations in Europe, the Middle East, Africa, Asia and Australasia, (ii) car sharing operations in certain of these markets, and (iii) licensees in the areas in which do not operate directly.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.